Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary Intervention

Hypertension Clinical Trial

Official title:

Effect of Innovative Natural Dietary Formulation on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration: Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04403347
• Other study ID #: 2017-GZ10 (Part II)
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 8, 2021
• Est. completion date: September 30, 2023

Study information

• Verified date: October 2022
• Source: Chinese Academy of Medical Sciences, Fuwai Hospital
• Contact: LUYUN FAN, MD
• Phone: 01088392165
• Email: fuwai_fanluyun[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mounting preclinical and clinical evidences have proved the optimal role of diets (i.e. DASH (Dietary Approaches to Stop Hypertension) diet, Mediterranean diet) on BP control and a causal role of gut microbiota on the pathogenesis of primary hypertension. Dietary changes appeared to reshape gut microbiota and to ameliorate diseases such as Type 2 Diabetes. A hypothesis is thus raised that dietary changes can be a potential approach to ameliorate hypertension via gut microbiome restoration. This pilot study will utilize an innovative natural dietary formulation (patent ID: CN110250417A), in comparison with classic antihypertensive treatment (losartan 50mg per day) and usual care (guideline-based patient education and lifestyle recommendations), to investigate its effect and safety on primary hypertension treatment, and the underlying mechanisms of gut microbiome restoration.

Description:

Primary hypertension is a most prevalent cardiovascular diseases, and becomes a severe global public health issue because of the high morbidity and potential risk to other cardiovascular diseases. Several animal studies and diverse patient cohorts reported that the disorder of gut microbiome correlated with hypertension. Based on the investigators' previous work findings of metagenomics analysis, fecal transplantation and metabolomics changes in hypertension and pre-hypertension patients, a casual role of gut microbiome disorder was observed in primary hypertension and raised a hypothesis that gut microbiome restoration can be a potential approach to ameliorate hypertension. Recent studies indicated FMT, prebiotics, probiotics, dietary changes and other methodologies can assist gut microbiome restoration in diseases such as type 2 diabetes. The investigators therefore develop two pilot studies respectively utilizing FMT capsules (Pilot Study I) and innovative dietary changes (Pilot Study II) to explore the methodologies, effect, safety and underlying mechanisms of gut microbiome restoration on hypertension. These pilot studies also present as the clinical translational part of the research project "The Role of Gut Microbiome in the Pathogenesis of Essential Hypertension"(Project ID 81630014, sponsored by National Natural Science Foundation of China).

This study is the Pilot Study II:

Objective: With reference of DASH diet and Mediterranean diet, this study aims to explore the effect and safety of an innovative natural dietary formulation on primary hypertension, and the underlying mechanisms of gut microbiome restoration.

Study Design: A multicenter, randomized, open-label, positive- and negative- controlled, pilot study.

Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality.

Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: September 30, 2023
• Est. primary completion date: January 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Age 18~60 years.

2. Established Diagnosis of Grade 1 Hypertension (initial diagnosis or free from antihypertensive drugs within a month): 140mmHg= Office SBP<160mmHg for three measurements at different days without any antihypertensive medications, according to the "2010 Chinese Guidelines for Prevention and Treatment of Hypertension".

3. Patients with informed consent after thorough explanation.

Exclusion Criteria:

1. Antibiotics or probiotics usage within last 4 weeks

2. Participants of other clinical trials related to hypertension currently or within last 3 months

3. Antihypertensive medications usage currently or within last month

4. Diagnosed secondary hypertension

5. Severe hepatic or renal diseases ((ALT >3 times the upper limit of normal value, or end stage renal disease on dialysis or eGFR <30 mL/min/1.73 m2, or serum creatinine >2.5 mg/dl [>221 µmol/L])

6. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack [TIA])

7. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 12 months.

8. Sustained atrial fibrillation or arrhythmias at recruitment disturbing the electronic BP measurement.

9. NYHA class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months.

10. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period.

11. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease.

12. Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome.

13. Cognitive impairment or severe neuropsychiatric comorbidities who are incapable of providing their own informed consent.

14. Participants preparing for or under pregnancy and/or lactation.

15. Other conditions inappropriate for recruitment according to the investigators.

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Dietary Supplement:
• Innovative Dietary Formulation (Patent ID: CN110250417A)
In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.

Drug:
• Losartan 50mg per day
In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).

Locations

Country	Name	City	State
China	Clinical Medical College&Affiliated Hospital of Chengdu University	Chengdu	Sichuan
China	First Affiliated Hospital of Chongqing Medical University	Chongqing
China	First Affiliated Hospital of Jinan University	Guangzhou	Guangdong
China	Second Affiliated Hospital of Shantou University Medical College	Shantou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital	National Natural Science Foundation of China

Country where clinical trial is conducted

China, 

References & Publications (3)

Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017 Feb 1;5(1):14. doi: 10.1186/s40168-016-0222-x. — View Citation

Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, Kaye DM. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation. 2017 Mar 7;135(10):964-977. doi: 10.1161/CIRCULATIONAHA.116.024545. Epub 2016 Dec 7. — View Citation

Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, Yu L, Xu C, Ren Z, Xu Y, Xu S, Shen H, Zhu X, Shi Y, Shen Q, Dong W, Liu R, Ling Y, Zeng Y, Wang X, Zhang Q, Wang J, Wang L, Wu Y, Zeng B, Wei H, Zhang M, Peng Y, Zhang C. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018 Mar 9;359(6380):1151-1156. doi: 10.1126/science.aao5774. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change for Office Systolic Blood Pressure (SBP)	Change for Office Systolic Blood Pressure (SBP)	Baseline, Month 1, Month 2, Month 3
Secondary	Change for Office Diastolic Blood Pressure (DBP)	Change for Office Diastolic Blood Pressure (DBP)	Baseline, Month 1, Month 2, Month 3
Secondary	Change for daytime average SBP via 24-hour Ambulatory BP Monitoring	Change for daytime average SBP via 24-hour Ambulatory BP Monitoring	Baseline, Month 1, Month 2, Month 3
Secondary	Change for daytime average DBP via 24-hour Ambulatory BP Monitoring	Change for daytime average DBP via 24-hour Ambulatory BP Monitoring	Baseline, Month 1, Month 2, Month 3
Secondary	Change for nighttime average SBP via 24-hour Ambulatory BP Monitoring	Change for nighttime average SBP via 24-hour Ambulatory BP Monitoring	Baseline, Month 1, Month 2, Month 3
Secondary	Change for nighttime average DBP via 24-hour Ambulatory BP Monitoring	Change for nighttime average DBP via 24-hour Ambulatory BP Monitoring	Baseline, Month 1, Month 2, Month 3
Secondary	Number of Participants with Adverse Events (AEs) as a Measure of Safety	Number of Participants with Adverse Events (AEs) as a Measure of Safety	All AEs over 3 months
Secondary	Intestinal Microbiota Composition Pre- and Post-intervention (innovative dietary formulation, losartan 50mg per day, or usual care) via Metagenomic Analysis	Intestinal Microbiota Composition Pre- and Post-intervention (innovative dietary formulation, losartan 50mg per day, or usual care) via Metagenomic Analysis	Baseline, Month 1,Month 2,Month 3
Secondary	Intestinal Microbiota function Pre- and Post-intervention (innovative dietary formulation, losartan 50mg per day, or usual care) via Metagenomic Analysis	Intestinal Microbiota function Pre- and Post-intervention (innovative dietary formulation, losartan 50mg per day, or usual care) via Metagenomic Analysis	Baseline, Month 1,Month 2,Month 3
Secondary	Intestinal and Serum Metabolite Composition Pre- and Post-intervention (innovative dietary formulation, losartan 50mg per day, or usual care) via Metabolomic Analysis	Intestinal and Serum Metabolite Composition Pre- and Post-intervention (innovative dietary formulation, losartan 50mg per day, or usual care) via Metabolomic Analysis	Baseline, Month 1,Month 2,Month 3
Secondary	Change for Fasting Blood Glucose Level	Change for Fasting Blood Glucose Level	Baseline, Month 2
Secondary	Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)	Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)	Baseline, Month 2
Secondary	Change for Body Mass Index	Change for Body Mass Index	Baseline, Month 2